Conflict of interest
Cancer
CANCER
JSW reports stock ownership in Biond, CytoMx, Evaxion, NexImmune, and Protean; receiving consulting or advisory fees from AstraZeneca, Biond, Bristol Myers Squibb (BMS), Celldex, CytomX, Evaxion, GlaxoSmithKline (GSK), Genentech, Idera, Incyte, Merck, NexImmune, Novartis, OncoSec, Pfizer, Ultimovacs, Regeneron, and Sellas; receiving research funding from BMS, GSK, Merck, Moderna, Novartis, and Regeneron; holding patents issued for a PD-1 biomarker named by Biodesix and a CTLA-4 biomarker named by Moffitt Cancer Center. TP reports being an employee of BMS with stock ownership in BMS. BDS reports being an employee of BMS with stock ownership in AbbVie, BMS, and Gilead Sciences Inc. LAS reports being an employee of BMS with stock ownership in BMS. EXD reports being an employee of the Analysis Group, Inc., which received consultancy fees from BMS for conducting the research analysis for the work under consideration. TW reports being an employee of the Analysis Group, Inc., which received consultancy fees from BMS for conducting the research analysis for the work under consideration. YC reports being an employee of the Analysis Group, Inc., which received consultancy fees from BMS for conducting the research analysis for the work under consideration. YW reports being an employee of the Analysis Group, Inc., which received consultancy fees from BMS for conducting the research analysis for the work under consideration. KAB reports being an employee of the Analysis Group, Inc., which received consultancy fees from BMS for conducting the research analysis for the work under consideration. ANS reports receiving advisory or personal fees from BMS, Immunocore, and Novartis; receiving research funding to his institution from BMS, Checkmate Pharmaceuticals, Foghorn Therapeutics, Immunocore, Novartis, Pfizer, Polaris, Targovax, and Xcovery.